DK3065764T3 - Mini-gastrin-analog, især til anvendelse ved CCK2-receptor-positiv tumordiagnose og/eller -behandling - Google Patents
Mini-gastrin-analog, især til anvendelse ved CCK2-receptor-positiv tumordiagnose og/eller -behandling Download PDFInfo
- Publication number
- DK3065764T3 DK3065764T3 DK14795569.4T DK14795569T DK3065764T3 DK 3065764 T3 DK3065764 T3 DK 3065764T3 DK 14795569 T DK14795569 T DK 14795569T DK 3065764 T3 DK3065764 T3 DK 3065764T3
- Authority
- DK
- Denmark
- Prior art keywords
- mini
- dgiu
- gastrin
- dglu
- analogue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57572—Gastrin releasing peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (10)
1. Mini-gastrin-analog PP-F11 med formlen: PP-F11: X-DGIu-DGIu-DGIu-DGIu-DGIu-DGIu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, hvor Y står for en aminosyre, der erstatter methionin, og X står for en kemisk gruppe bundet til peptidet med henblik på diagnostisk og/eller terapeutisk intervention ved CCK-2-receptor-relevante sygdomme.
2. Mini-gastrin-analog PP-F11 ifølge krav 1, hvor methionin er erstattet af norleucin for at tilvejebringe mini-gastrin-analog PP-F11N.
3. Mini-gastrin-analog PP-F11 ifølge krav 1 eller 2, hvor X står for et radionu-klid omfattende en chelator til radiometaller.
4. Mini-gastrin-analog PP-F11 ifølge krav 3, hvor chelatoren til radiometaller er DOTA.
5. Mini-gastrin-analog PP-F11 ifølge krav 3, hvor radionuklidet er udvalgt fra gruppen bestående af 177Lu, 90Y og 111 In.
6. Mini-gastrin-analog PP-F11 ifølge krav 2, hvor PP-F11N yderligere er defineret som: DOTA-DGIu-DGIu-DGIu-DGIu-DGIu-DGIu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2.
7. Mini-gastrin-analog PP-F11 ifølge krav 6, hvor DOTA-DGIu-DGIu-DGIu-DGIu-DGIu-DGIu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 er mærket med 177Lu.
8. Mini-gastrin-analog PP-F11 ifølge krav 1 eller 2, hvor X står for en optisk aktiv kemisk forbindelse.
9. Mini-gastrin-analog PP-F11 ifølge krav 1 eller 2, hvor X står for en kemoterapeutisk aktiv forbindelse.
10. Mini-gastrin-analog PP-F11 ifølge krav 1 eller 2, hvor X står for en na-nopartikel eller et liposom, som har en diagnostisk funktion (fx optisk aktiv eller MRI-kontrastmiddel), eller som har en terapeutisk funktion i sig selv eller er ladet med en aktiv forbindelse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20130191807 EP2870972A1 (en) | 2013-11-06 | 2013-11-06 | Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment |
| PCT/EP2014/072697 WO2015067473A1 (en) | 2013-11-06 | 2014-10-23 | Mini-gastrin analogue, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3065764T3 true DK3065764T3 (da) | 2018-03-12 |
| DK3065764T6 DK3065764T6 (da) | 2023-11-06 |
Family
ID=49518847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14795569.4T DK3065764T6 (da) | 2013-11-06 | 2014-10-23 | Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10130724B2 (da) |
| EP (2) | EP2870972A1 (da) |
| JP (3) | JP2017501116A (da) |
| KR (2) | KR20160070160A (da) |
| CN (1) | CN105705159B (da) |
| CY (1) | CY1120117T1 (da) |
| DK (1) | DK3065764T6 (da) |
| ES (1) | ES2670582T7 (da) |
| HR (1) | HRP20180631T1 (da) |
| HU (1) | HUE036943T2 (da) |
| LT (1) | LT3065764T (da) |
| NO (1) | NO3065764T3 (da) |
| PL (1) | PL3065764T6 (da) |
| PT (1) | PT3065764T (da) |
| RS (1) | RS57137B1 (da) |
| SI (1) | SI3065764T1 (da) |
| SM (1) | SMT201800240T1 (da) |
| TR (1) | TR201802723T4 (da) |
| WO (1) | WO2015067473A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2870972A1 (en) * | 2013-11-06 | 2015-05-13 | Paul Scherrer Institut | Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment |
| US10786580B2 (en) * | 2016-09-09 | 2020-09-29 | On Target Laboratories, LLC | Cholecystokinin 2 receptor targeted NIR imaging and use thereof |
| EP3412303A1 (en) | 2017-06-08 | 2018-12-12 | Medizinische Universität Innsbruck | Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy |
| EP3459559A1 (en) | 2017-09-21 | 2019-03-27 | Paul Scherrer Institut | Minigastrin derivates, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment |
| WO2019245038A1 (ja) | 2018-06-22 | 2019-12-26 | 株式会社Ｊｕｎｔｅｎ Ｂｉｏ | 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法 |
| TWI854983B (zh) | 2018-06-22 | 2024-09-11 | 日商順天生化股份有限公司 | 誘導免疫耐受之抗體、被誘導之淋巴球、及使用被誘導之淋巴球之細胞治療劑治療方法 |
| TWI832868B (zh) | 2018-06-22 | 2024-02-21 | 日商順天生化股份有限公司 | 用於誘發感染性免疫耐受之組合物 |
| EP3868394A1 (en) * | 2020-02-20 | 2021-08-25 | Paul Scherrer Institut | Mono- and multi-triazolominigastrins for targeting of cck2r-positive neoplasms |
| WO2021186060A1 (en) | 2020-03-20 | 2021-09-23 | Debiopharm International S.A. | Radiolabeled gastrin analogue for use in a method of treating and/or imaging cckb receptor positive diseases, in particular pulmonary and extrapulmonary small-cell carcinoma |
| EP4188456A1 (en) * | 2020-07-31 | 2023-06-07 | Paul Scherrer Institut | Alpha radiolabeled gastrin analogue and use thereof in methods of treating cckb receptor positive disease |
| KR102928594B1 (ko) * | 2020-07-31 | 2026-02-23 | 폴 슈레 앙스띠뛰 | 특히, cckb 수용체 양성 암 또는 종양의 치료 및/또는 진단에서 사용하기 위한, 라파로그 및 방사성표지된 가스트린 유사체를 포함하는 조성물 |
| KR20230044463A (ko) * | 2020-07-31 | 2023-04-04 | 폴 슈레 앙스띠뛰 | 갈륨-표지된 가스트린 유사체 및 cckb 수용체 양성 종양 또는 암의 영상화 방법에서의 용도 |
| AU2021426543A1 (en) | 2021-02-02 | 2023-09-21 | Medizinische Universität Innsbruck | Improved cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy |
| US20240401145A1 (en) | 2021-09-28 | 2024-12-05 | Paul Scherrer Institut | Method for predicting the response of a patient diagnosed with cancer to treatment and/or imaging with a compound targeting cck2-r, and compound for use in methods of selectively treating and/or imaging cancer |
| CN113929737B (zh) * | 2021-10-20 | 2024-07-23 | 中国科学院香港创新研究院再生医学与健康创新中心 | 一种多肽及其作为cck受体激动剂/拮抗剂的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650787A (en) | 1985-04-25 | 1987-03-17 | Schally Andrew Victor | Biologically active octapeptides |
| EP2870972A1 (en) * | 2013-11-06 | 2015-05-13 | Paul Scherrer Institut | Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment |
-
2013
- 2013-11-06 EP EP20130191807 patent/EP2870972A1/en not_active Withdrawn
-
2014
- 2014-10-23 ES ES14795569T patent/ES2670582T7/es active Active
- 2014-10-23 TR TR2018/02723T patent/TR201802723T4/tr unknown
- 2014-10-23 RS RS20180451A patent/RS57137B1/sr unknown
- 2014-10-23 US US15/034,943 patent/US10130724B2/en active Active
- 2014-10-23 HU HUE14795569A patent/HUE036943T2/hu unknown
- 2014-10-23 PT PT147955694T patent/PT3065764T/pt unknown
- 2014-10-23 SI SI201430693T patent/SI3065764T1/en unknown
- 2014-10-23 WO PCT/EP2014/072697 patent/WO2015067473A1/en not_active Ceased
- 2014-10-23 PL PL14795569.4T patent/PL3065764T6/pl unknown
- 2014-10-23 CN CN201480061076.3A patent/CN105705159B/zh active Active
- 2014-10-23 SM SM20180240T patent/SMT201800240T1/it unknown
- 2014-10-23 HR HRP20180631TT patent/HRP20180631T1/hr unknown
- 2014-10-23 LT LTEP14795569.4T patent/LT3065764T/lt unknown
- 2014-10-23 EP EP14795569.4A patent/EP3065764B3/en active Active
- 2014-10-23 KR KR1020167014687A patent/KR20160070160A/ko not_active Withdrawn
- 2014-10-23 JP JP2016528150A patent/JP2017501116A/ja not_active Ceased
- 2014-10-23 NO NO14795569A patent/NO3065764T3/no unknown
- 2014-10-23 KR KR1020187022942A patent/KR102039930B1/ko active Active
- 2014-10-23 DK DK14795569.4T patent/DK3065764T6/da active
-
2018
- 2018-04-03 JP JP2018071479A patent/JP6568618B2/ja active Active
- 2018-04-03 CY CY20181100368T patent/CY1120117T1/el unknown
- 2018-10-11 US US16/157,961 patent/US10953114B2/en active Active
-
2019
- 2019-08-02 JP JP2019142770A patent/JP6763069B2/ja active Active
-
2020
- 2020-12-18 US US17/127,265 patent/US11623014B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11623014B2 (en) | Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment | |
| Smith et al. | Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update | |
| Antunes et al. | Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? | |
| Durkan et al. | A heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors | |
| CN116585494A (zh) | 癌症诊断成像剂 | |
| US8986651B2 (en) | Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | |
| EP3684395B1 (en) | Minigastrin derivates, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment | |
| WO2012118909A1 (en) | Radiolabelled octreotate analogues as pet tracers | |
| Jia et al. | Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting | |
| Hausner et al. | The effects of an albumin binding moiety on the targeting and pharmacokinetics of an integrin αvβ6-selective peptide labeled with aluminum [18F] fluoride | |
| Koumarianou et al. | Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation | |
| US20140147385A1 (en) | Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | |
| Ishizaki et al. | Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives | |
| Pujatti et al. | Development of a new bombesin analog radiolabeled with lutetium-177: in vivo evaluation of the biological properties in balb-c mice | |
| Obeid et al. | Improving GRPR-targeting peptides for radiotheranostics application: insights from chelator modifications and α-methyl-L tryptophan substitution | |
| De et al. | Radiolabeled novel peptide for imaging somatostatin-receptor expressing tumor: synthesis and radiobiological evaluation | |
| CN121013861A (zh) | 具有生物分布调节剂的抑胃肽受体配体 | |
| Pourghiasian | Novel radiolabeled peptides to improve breast and prostate cancer diagnosis by PET | |
| Edwards et al. | Synthesis and radiolabeling of a somatostatin analog for multimodal imaging | |
| So-Young et al. | Reducing Renal Uptake of 177 Lu Labeled CCK Derivative using Basic Amino Acids | |
| HK1196006A (en) | Radiolabelled octreotate analogues as pet tracers |